Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Monogenic diabetes caused by inactivating mutation(s) in the gene HNF4A, encoding hepatocyte nuclear factor 4-alpha.
Features include: Flushing and Maturity-onset diabetes of the young.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Hormones | 1 | Maturity-onset diabetes of the young |
HNF4A encodes hepatocyte nuclear factor 4 alpha (474 aa). Transcriptional regulator which controls the expression of hepatic genes during the transition of endodermal cells to hepatic progenitor cells, facilitating the recruitment of RNA pol II to the promoters of target genes. Highest expression in Liver (55.4 TPM) and Colon Transverse (33.0 TPM).
Maturity-onset diabetes of the young type 1 is associated with mutations in the HNF4A gene on chromosome 20.
The HNF4A protein participates in HNF4A (pancreas-specific), HNF1A-dependent synthesis of HNF4A, and Expression of HNF4A during nephron development pathways.
HNF4A is classified as a druggable target (Druggable Genome, Nuclear Hormone Receptor, and Transcription Factor categories) with score 1.6.
Genetic testing for HNF4A is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for maturity-onset diabetes of the young type 1 has been reported in the published literature.
No clinical trials have been registered for maturity-onset diabetes of the young type 1.
113 publications have been identified in PubMed for maturity-onset diabetes of the young type 1. Research spans Review / Meta-Analysis (31%), Basic Science / Preclinical (24%), and Case Report / Case Series (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 35 | 31% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:27 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Laboratory research
27 |
24% |
Patient case studies | 18 | 16% |
Disease patterns and progression | 16 | 14% |
Testing and diagnosis research | 7 | 6% |
Clinical study results | 5 | 4% |
Other research | 4 | 4% |
New treatment approaches | 1 | 1% |
Scala R (2026). [PMID: 40272924](https://pubmed.ncbi.nlm.nih.gov/40272924/). *Diabetes*. [Epidemiology / Natural History]
Miao H (2026). [PMID: 41849234](https://pubmed.ncbi.nlm.nih.gov/41849234/). *Blood*. [Basic Science / Preclinical]
Asamoah A (2026). [PMID: 41751598](https://pubmed.ncbi.nlm.nih.gov/41751598/). *Genes (Basel)*. [Review / Meta-Analysis]
Takasugi Y (2026). [PMID: 42147507](https://pubmed.ncbi.nlm.nih.gov/42147507/). *Cureus*. [Case Report / Case Series]
Yoshiji S (2026). [PMID: 40853921](https://pubmed.ncbi.nlm.nih.gov/40853921/). *J Clin Endocrinol Metab*. [Basic Science / Preclinical]
Myers R (2026). [PMID: 40746173](https://pubmed.ncbi.nlm.nih.gov/40746173/). *J Clin Endocrinol Metab*. [Diagnostic / Biomarker]
Sharp LN (2026). [PMID: 41288518](https://pubmed.ncbi.nlm.nih.gov/41288518/). *Diabetes*. [Case Report / Case Series]
Zhang T (2026). [PMID: 41206949](https://pubmed.ncbi.nlm.nih.gov/41206949/). *J Natl Cancer Inst*. [Basic Science / Preclinical]
Zeljkovic A (2026). [PMID: 41318290](https://pubmed.ncbi.nlm.nih.gov/41318290/). *J Diabetes Complications*. [Other]
Relan S (2026). [PMID: 40554608](https://pubmed.ncbi.nlm.nih.gov/40554608/). *J Clin Endocrinol Metab*. [Epidemiology / Natural History]